Trial Profile
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 15 Jun 2023 Results of an analysis assessing matching-adjusted indirect comparison (MAIC) of Pirtobrutinib vs Venetoclax continuous monotherapy from two clinical trials: NCT03740529 and NCT02141282 presented at the 28th Congress of the European Haematology Association
- 29 Dec 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results (n=1138) of a retrospective analysis assessing rates of tumor lysis syndrome and outcomes and data were pooled from eight clinical studies: M15-550, M15-889, CLL14, M16-778, M14-032, M13-982, M14-728 and MURANO presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology